CD274 and cancer: Recent findings have shown that PD-L1 overexpression on cancer cells evades antitumor immunity, but upregulated PD-L1 improves ICB therapy efficacy in a mouse model [57, 58] and sensitizes immunotherapy-resistant tumors to ICB therapy [59].